Scailyte and Volv Global Enter Strategic Partnership
February 24, 2021
Rare Daily Staff
Scailyte and Volv Global, companies harnessing artificial intelligence to discover novel biomarkers, entered a strategic partnership to develop a patient identification and diagnostic platform for rare diseases.
Volv Global identifies digital disease biomarkers by screening patient electronic health records with a unique automated disease learning platform inTrigue, and Scailyte leverages its single-cell data analysis platform ScaiVision to identify and validate disease-specific molecular biomarkers.
Through the joint venture, Volv Global will identify potential patients with rare or difficult to diagnose diseases who can then be enrolled in molecular biomarker discovery studies led by Scailyte and clinical key opinion leaders in the disease area.
The two companies said the effort will allow undiagnosed or misdiagnosed patients to be treated appropriately much earlier, clinicians will have tools for an informed diagnosis, and pharmaceutical companies will be able to provide therapies to the target population with high response rates.
“We are learning more and more about rare diseases, for example, that what might once have been thought of as a single rare disease is actually multiple rare diseases that have been classified under a single category,” said Christopher Rudolf, CEO of Volv Global. “This is why so many patients remain undiagnosed or misdiagnosed. The partnership between Volv and Scailyte has the potential to dramatically improve the journey to diagnosis and treatment for patients. The synergies between our two companies offer an important value proposition to patients, clinicians and pharma companies.”
Photo: Christopher Rudolf, CEO of Volv Global
Sign up for updates straight to your inbox.